Clinical trial
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT05169437
Study timeline
Study start (actual)2022-03-15Date precision: day
Registry last updated2025-10-29
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumorunresolved
Breast Tumorunresolved
Colon Tumor, Malignantunresolved
Lung Tumorunresolved
Urologic Cancerunresolved
Pancreatic Cancerunresolved
Melanomaunresolved
Metastatic Cancerunresolved
Locally Advanced Solid Tumorunresolved
Esophageal Cancerunresolved
Endometrial Cancerunresolved
Head and Neck Cancerunresolved
Interventions
NiraparibDRUG · verified · RxNorm: niraparib
Sponsors & collaborators
Tempus AIlead sponsor
GlaxoSmithKlinecollaborator
Mapped research locations
DallasTexas, United States3AustinTexas, United States3ClevelandOhio, United States2RichmondVirginia, United States2Sioux FallsSouth Dakota, United States2HoustonTexas, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1NashvilleTennessee, United States1CincinnatiOhio, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05169437 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.